April 2, 2026
Today, on April 2, President Trump signed a proclamation updating Section 232 tariffs on steel, aluminum, and copper, alongside a separate executive order targeting pharmaceutical imports.
According to a White House fact sheet, the proclamation changes how tariffs are calculated so they reflect the true value of imported metal products, rather than lower foreign pricing.
Under the updated framework, tariffs will be applied as follows:
The administration stated that these revised tariff rates will take effect at 12:01 a.m. ET on April 6, 2026. Additional details are available in Annexes I-A, I-B, II, III, and IV.
Separately, the executive order introduces pharmaceutical import tariffs under Section 232. Patented drugs and their ingredients will be subject to a 100% tariff, with implementation timelines of 120 days for larger companies and 180 days for smaller firms.
There are exceptions: Pharmaceutical imports from the European Union, Japan, South Korea, Switzerland, and Liechtenstein will face a reduced 15% tariff. Products from the United Kingdom will be subject to an even lower rate under a newly finalized UK pharmaceutical agreement.
Companies that enter into both Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services and domestic production (onshoring) agreements with the Department of Commerce will qualify for a 0% tariff through January 20, 2029. Firms that only commit to onshoring agreements will face a 20% tariff.
The Departments of Commerce and HHS will outline processes for companies to participate in these agreements, according to the accompanying fact sheet.
The administration also emphasized that the proclamation includes strict enforcement measures, such as external audits and the potential for retroactive and increased tariffs on non-compliant imports.
We will update this page with official CBP Guidance once it becomes available.